Bowel and Bladder Reproducibility in Image Guided Radiation Therapy for Prostate Cancer: Results of a Patterns of Practice Survey

Lindsay S. Rowe, MD, a,* Jeremy J. Mandia, MD, b Kilian E. Salerno, MD, c Uma T. Shankavaram, PhD, c Shaoli Das, PhD, c Freddy E. Escorcia, MD, PhD, c,d Holly Ning, PhD, c and Deborah E. Citrin, MD c

a Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada; b Walter Reed National Military Medical Center, Washington, DC; c Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland; d Molecular Imaging Branch, National Cancer Institute, Bethesda, Maryland

Received August 17, 2021; accepted December 16, 2021

Abstract

Purpose: Optimal management of patients with prostate cancer (PCa) to achieve bowel and bladder reproducibility for radiation therapy (RT) and the appropriate planning target volume (PTV) expansions for use with modern image guidance is uncertain. We surveyed American Society of Radiation Oncology radiation oncologists to ascertain practice patterns for definitive PCa RT with respect to patient instructions and set up, daily image guidance, and subsequent PTV expansions.

Methods and Materials: A pattern of practice survey was sent to American Society of Radiation Oncology radiation oncologists who self-identified as specializing in PCa. Respondents identified the fractionation regimens routinely used, and their practices regarding diet, bowel, and bladder instructions for patients with PCa before RT simulation and throughout treatment. Questions regarding PTV margins, daily set up practices, and use of image guidance were included.

Results: Of 190 respondents, 158 reported using conventional fractionation (CFx), 49 moderate hypofractionation (MHFx), and 61 stereotactic body radiation therapy (SBRT). Diet modifications during RT were advised by 84% of respondents, treatment with full bladder by 96%, and bowel instructions by 78%. Prescription of bowel medication was higher for respondents using SBRT (95.1%) versus those using CFx/MHFx (55.1%; 34.7%). The most common implantable device reported was fiducial markers, with increased use in SBRT (86.0%; 68.9%) versus CFx/MHFx. Cone beam computed tomography was the most common daily imaging technique across fractionation regimens. SBRT showed correlation between PTV margin expansions, fiducial marker use, and image guidance.

Conclusions: Survey results indicate heterogeneity in treatment modality, dose, patient instructions, and PTV expansions used by radiation oncologists in the treatment of patients with PCa. Further investigation to define appropriate patient instructions on bowel preparation to maximize target reproducibility in PCa is needed, as is continued guidance on evidence-based approaches for image guidance and PTV margin selection.

Sources of support: This research was funded by the intramural research program at the National Cancer Institute (grant No. ZID BC 010990).

Disclosures: Dr Salerno reports the following: American College of Radiology (TXIT examination committee chair, travel expenses); International Journal of Radiation Oncology, Biology, and Physics (associate senior editor); Journal of Surgical Oncology (associate editor); Johnson & Johnson (stock-family member). All other authors have no disclosures to declare.

Data sharing statement: Research data are stored in an institutional repository and will be shared upon request to the corresponding author.

*Corresponding author: Lindsay S. Rowe, MD; E-mail: lindsay.rowe@ahs.ca

https://doi.org/10.1016/j.adro.2022.100902

2452-1094 © 2022 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

Current practice guidelines for the definitive management of localized prostate cancer (PCa) include a variety of radiotherapeutic options, including brachytherapy, conventionally fractionated external beam radiation therapy (CFx), moderately hypofractionated radiation therapy (MHFx), and ultrahypofractionated regimens, such as stereotactic body radiation therapy (SBRT)/stereotactic ablative radiation therapy. Patterns of practice have shifted over the past decade, with increased utilization of hypofractionated and stereotactic regimens based on data suggesting equivalent outcomes relative to CFx with these approaches. These initial large series of altered fractionation schemas used varying preparative regimens before simulation or treatment, with differing treatment planning margins and image guided radiation therapy (RT) approaches.

Few published evidence-based guidelines define the optimal bowel or bladder regimens, localization methods, and planning margins for these various fractionation regimens. Therefore, we conducted a national pattern of practice survey to identify how radiation oncologists interpret and implement the available data and manage their patients with PCa when using CFx, MHFx, and SBRT. Herein, we report the results of this survey and the practice patterns related to bladder and bowel preparation for simulation and treatment, image guidance approaches, and planning target volume (PTV) margin expansions used for different fractionation regimens.

Methods and Materials

Survey development

The proposed research was reviewed and determined exempt by an institutional review board and office of human subjects protection. To create the survey, we conducted a literature review of the current evidence regarding dietary, bowel, and bladder instructions; use of image guidance; and PTV margin expansion recommendations for the simulation and treatment of patients with PCa. We then developed a radiation oncology-specific practice pattern survey based on this evidence, available guidelines, and previously published questionnaires. The survey then underwent an additional review by a selected group of genitourinary radiation oncologists before dissemination.

Survey questions addressed overall practice patterns using definitive external beam RT for the treatment of PCa. On the questionnaire, CFx was defined as 180 to 200 cGy per fraction, MHFx as >200 to 500 cGy per fraction, and SBRT as >500 cGy per fraction. Dose escalated conventional fractionation (CFx-DE) was defined as >7800 cGy. Other questions captured respondent demographics, treatment modalities used, patient instructions on bowel and bladder preparation for simulation and treatment, use of implantable devices, daily image guidance, and size of PTV margin expansions (Supplementary Material).

Sample selection and survey distribution

Invitations including a link to the survey were sent via e-mail to American Society of Radiation Oncology (ASTRO) members in the United States who self-identified as radiation oncologists specializing in prostate cancer. Surveys were collected between June and October 2018. Responses were included in the analysis if the respondent provided at minimum their radiation oncology, superior, inferior) were grouped as >5 mm, >5 mm, or >10 mm. Moderate and strong correlations were considered r ≥ 0.5, and r ≥ 0.7, respectively.

Results

Demographic information

An initial 1395 survey requests were sent by e-mail. A total of 190 (13.6%) respondents completed the questionnaire with adequate information for analysis. Respondent demographic information is listed in Table 1. Most respondents had been in practice >10 years, with two-thirds practicing in a hospital system, and one-third practicing in a free-standing clinic or satellite clinic. Over half
Of the 190 respondents, 83.1% (158/190) reported treating with CFx, 48.7% (77/158) of whom used dose escalation above 7800 cGy. SBRT use was reported by 33.7% (61/190) of respondents and MHFx by 25.8% (49/190). Intensity modulated RT was the most commonly used modality for radiation delivery (97.4%; 185/190). Less than 10% reported using TomoTherapy (8.9%; 17/190), proton therapy (6.3%; 12/190), or photon 3-dimensional conformal RT (1.6%; 3/190). For SBRT, 75.4% of respondents used doses of $>500$ to $\leq725$ cGy per fraction, with few using $\geq800$ cGy per fraction (14.7%) and a single respondent using 950 cGy per fraction (Table 1).

Diet recommendations

The majority of respondents reported providing some diet recommendations before simulation (77.9%; 148/190) and during treatment (83.7%; 159/190), though specific recommendations varied. Provision of diet recommendations did not differ for fractionation regimens at simulation and during treatment, with specific recommendations presented in Figure 1. Diet recommendations at simulation for CFx and MHFx were, however, more common among respondents in private (83.8%) versus academic practice (63.2%) and among those with $>20$ patients on treatment at a time (100% vs 69.4%) ($P < .006$).

Bladder and bowel recommendations

Bladder protocols for set up and reproducibility were consistently advised, with 95.8% of respondents (182/190) reporting that they direct patients to have a comfortably full bladder for simulation and treatment. The remaining 8 respondents reported treating with empty bladders. There were no significant differences in the rates of bladder instructions between fractionation regimens.

In contrast, there was more variation among survey respondents regarding frequency and type of bowel protocol recommendations (ie, any bowel instructions or directions) between different fractionation approaches. Most respondents (>76%) provide bowel recommendations to patients at simulation and treatment, without significant difference by fractionation schemes (Fig. 2). Bowel recommendations included instruction to patients to empty bowels before simulation/treatment, directives on bowel regimens, and prescription of medications. When using

### Table 1 Radiation oncologist demographic and treatment information

| Demographic                              | n = 190 |
|------------------------------------------|---------|
| **Years in practice**                    |         |
| Currently in training                    | 1 (0.5%)|
| 0-5 y                                    | 53 (28%)|
| 6-10 y                                   | 33 (17%)|
| 11-20 y                                  | 47 (25%)|
| $\geq20$ y                               | 56 (29%)|
| **Primary practice location**            |         |
| Hospital                                 | 129 (68%)|
| Free-standing/satellite clinic           | 61 (32%)|
| **Primary employer**                     |         |
| Private practice/community-based system  | 109 (57%)|
| Academic/university system               | 65 (34%)|
| Government/public sector                 | 10 (5%) |
| Independent contractor/locum tenens      | 5 (2.5%)|
| Industry                                 | 1 (0.5%)|
| **Number of patients on treatment at a time** |       |
| 1-10                                     | 136 (72%)|
| 11-20                                    | 36 (19%) |
| $>20$                                    | 18 (9%)  |
| **Fractionation**                        |         |
| CFx (180-200 cGy)                        | 158 (83%)|
| CFx-DE ($>7800$ cGy)                     | 77 (49%) |
| MHFx (200-500 cGy per fraction)          | 49 (25%) |
| SBRT                                     | 61 (32.1%)|
| **Treatment technique for standard or MHFx** |       |
| Photon 3D conformal                      | 3 (1.5%) |
| IMRT                                     | 185 (97%)|
| VMAT                                     | 153 (81%)|
| Static IMRT                              | 72 (38%) |
| TomoTherapy                              | 17 (9%)  |
| Proton therapy                           | 12 (6%)  |
| **SBRT fractionation**                   | n = 61  |
| $\leq7.25$ Gy per fraction               | 46 (75%) |
| $>7.25$ Gy per fraction                  | 15 (25%) |
| $>7.25$ but $<8$ Gy per fraction         | 6 (10%)  |
| $\geq8$ Gy per fraction                  | 9 (15%)  |

*Abbreviations: 3D = 3-dimensional; CFx = conventional fractionation; CFx-DE = conventional fractionation-dose escalated; IMRT = intensity modulated radiation therapy; MHFx = moderate hypofractionation; SBRT = stereotactic body radiation therapy; VMAT = volumetric modulated arc therapy. * Respondents were allowed multiple responses.
CFx and MHFx, two-thirds or more of respondents asked patients to empty their bowels before simulation and treatment; however, this was less common with SBRT (Fig. 2). In lieu of having patients simply attempt to empty their bowels before treatment, significantly more SBRT respondents reported prescribing enemas (42.6% vs 6.3% vs 4.1%; $P < .00001$) (Table 2). Additionally, respondent in academic (87.1%) practices were significantly more likely to provide bowel recommendations at SBRT simulation than those in private practice (80%), as were those in practice 6 to 10 years (92.9%) versus >20 years (66.7%) ($P < .05$). The reported prescription of stool softeners, rectal suppositories, and laxatives were similar between fractionation regimens (Table 2). Regarding the subclasses of laxatives prescribed, reported use of stimulant, lubricant, and osmotic laxatives were similar between fractionation regimens, with lubricant laxatives rarely or never prescribed.

In addition to bladder and bowel preparative instructions, many respondents used consistent daily patient appointment times to improve set-up and filling reproducibility (62.6%; 119/190). Placement of hydrogel spacers varied between fractionation regimens, with 31.0% of respondents reporting use for CFx/CFx-DE (49/158), 36.7% (18/49) for MHFx, and 60.7% for SBRT (37/61), being significantly higher for SBRT ($P = .0001$) (Fig. 3).

**Implantable devices, image guidance, and reproducibility**

The respondents’ use of fiducial markers varied by treatment regimen. Overall, fiducial markers were used by the majority of respondents, but the use was highest for SBRT (CFx/CFx-DE 59.5%, 94/158; MHFx 57.1%, 28/49; and SBRT 80.3%, 49/61, $P = .006$) (Fig. 3). Use of radio-frequency transponders was less common overall, but similar between fractionation schemes (Fig. 3). Image guidance was used for set-up verification by the vast majority of respondents (94.7%, 180/190), with daily cone beam computed tomography (CBCT) being the predominant modality reported (97.2%), followed by daily 2-dimensional imaging (22.2%) (Fig. 3). Use of CyberKnife, TrueBeam Auto Beam Hold, or optical surface monitoring was reported by 30.0%.

Respondents were asked their management strategies when an organ position was out of tolerance during image guidance or set-up was not consistently reproducible. Most (75.3%) would ask patients to leave the couch and

---

**Figure 1** Diet recommendations for patients receiving radiation therapy at simulation (solid columns) and during radiation treatment (hashed columns) by conventional fractionation (CFx), moderately hypofractionated radiation (MHFx), or stereotactic body radiation therapy (SBRT).
defecate when rectal filling with excess stool was noted on CBCT. For consistent misalignment of organs, 66% of respondents reported they would resimulate the patient and replan. Reported criteria prompting resimulation included: organs outside of tolerance for ≥2 fractions, target consistently outside PTV, fiducial misalignment or migration, or when recalculated dose to organs at risk (OAR) on CBCT exceeded >3% from planned.

PTV margins

The PTV margin expansions for CFx, CFx-DE, and MHFx regimens were similar, with median PTV expansions of 6 mm (range, 3-10 mm) in the anterior, lateral, superior, and inferior directions, and less posteriorly with a median margin of 5 mm (range, 0-8 mm). The range of PTV expansions used for SBRT were broad, at 5 mm (range, 2-10 mm) for anterior, lateral, superior, and inferior margins, and the median margin posteriorly was 3 mm (range, 0-6 mm). Posterior PTV margin expansions for each fractionation scheme are presented in Figure 4.

Associations between PTV margin expansions, choice of image guidance, and implantable device use were evaluated. CFx, CFx-DE, and MHFx showed no correlation with PTV for use of implantable device or type of image guidance. However, for SBRT PTV margin expansion, moderate correlation was seen with smaller PTV expansions and hydrogel spacer use ($r = 0.66-0.70; P < .00001$), and strong correlation was seen with fiducial marker use ($r = 0.80-0.81$) and daily CBCTs ($r = 0.76-0.78; P < .00001$).

Discussion

Set-up reproducibility is critical for delivery of definitive RT for patients with localized PCa. Management
strategies to optimize, and account for, set-up reproducibility include patient preparative instructions, diet instructions, hydration, use of medications aimed to alter bowel function, use of fiducial markers, choice of image guidance modality and frequency, and subsequent PTV margin selection. Although some guidelines exist on use of daily image guidance, particularly for conventional fractionation, best practices and evidence-based guidelines are limited for other fractionation regimens.1-4 Additionally, evidence to support a benefit from dietary and prescription interventions and patient instructions regarding bowel and bladder preparation is limited and inconsistent, making it challenging to synthesize the data into uniform recommendations.24-29 Evidence supporting specific PTV margin expansions for various treatment modalities is available; however, individual radiation oncologists may tailor PTV margins in practice.30,31 This survey was created to provide additional data on individual patterns of practice for different fractionation regimens to supplement the existing literature.

Reproducibility of set-up and organ positioning is a critical component of fractionated external beam RT. Many behavioral interventions have been suggested to improve daily treatment reproducibility of the bladder and bowel filling. The vast majority of respondents instruct their patients to have a comfortably full bladder for simulation and treatment. On a recent survey of United Kingdom (UK) radiation oncology departments addressing practices for managing patients with PCa receiving RT, 92.5% of departments reported treating with a comfortably full bladder.32 Interestingly, and similar on both surveys, there were occasional recommendations to treat with an empty bladder (<10%).20 As maintaining a reproducible bladder volume over the course of treatment can be difficult, some oncologists may opt to treat with an empty bladder to improve consistency.32-35 Data support consistent bladder filling as key to achieving planned dose to OARs, with larger bladders at simulation demonstrating the most variation during treatment.36,37 Therefore, moderately full bladders, with small variations addressed via daily image guidance, may be the optimal approach for organ management in the modern era.

Bowel toxicity accounts for a significant amount of PCa quality of life concerns after RT.38 Differences in rectal and bowel position over the course of RT may significantly alter the dose received by these organs. Determining management strategies to increase reproducibility of bowel filling is an ongoing area of research.35,39 Dietary and behavioral modifications have been studied, including use of anti-flatulence medications, diets (high fiber, low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols, personalized), and probiotic use.26,29,40-42 Unfortunately, although some dietary interventions have shown promise, many have not, and the optimal diet approach to maintain reproducibility during RT remains uncertain.

Despite these uncertainties, most of respondents in the current study, and those in the UK study, provide patients with some type of diet recommendation before and during treatment.20 Both groups commonly recommend avoiding foods, drinks, and behaviors that produce gas, as supported by the available literature.41,42 Altering fiber intake was more commonly reported in this survey (24%-43%) compared with the UK departments (8.6%).20 The rationale for these differences is unclear; however, they may result from inconstant data regarding whether fiber alteration is of benefit, and if so, which option is superior.
For instance, the UK survey was split 50/50 as to whether they recommend high or low fiber diet pretreatment. Some physicians may develop a diet paradigm that works in their particular practices, as respondents with >20 patients on treatment at a time, in the current survey, were more likely to give diet instructions before treatment. Ultimately, there may not be a single intervention that demonstrates benefit for all patients, but future research may focus on modifications tailored to individual patient situations.

Figure 3  Reported use of implantable devices and image guidance by radiation fractionation regimen. (A) Use of implantable devices (n = 190 respondents). (B) Modalities of daily image guidance (n = 180 for those who provided responses). *Abbreviations: 2D = two-dimensional; CBCT = cone beam computed tomography; CFx = conventional fractionation including dose escalated; KV = kilo voltage; MHFx = moderate hypofractionation; SBRT = stereotactic body radiation therapy. *Includes radiofrequency transponders, CyberKnife, TrueBeam Auto Beam Hold, optical monitoring.

Figure 4  Reported posterior planning target volume expansions by radiation fractionation regimen. Abbreviations: CFx = conventional fractionation including dose escalated; MHFx = moderate hypofractionation; SBRT = stereotactic body radiation therapy.
Bowel instructions are employed by most respondents in this survey, which most often included emptying the bowel before simulation and treatment (73.2% and 87.2% respectively). This instruction is similar to the UK survey, in which 77.7% suggested emptying bowel before planning and radiation.20 This advice is supported by the literature, which suggests that emptying bowel decreases reproducibility and improves rectal dose-volume histogram throughout treatment.37,43

Prescription medications are also commonly used for prostate RT to minimize variation in bowel and rectal filling. As with diet modifications, some medications have shown promise while many others have not had a significant effect.20 Milk of Magnesia and magnesium oxide are some of the more extensively studied medications, often used with various diet interventions; however, reported efficacy has been mixed.25,37,40,42,44,45 One intervention that has shown benefit in reducing rectal size and improving OAR dosimetry in multiple clinical trials is the use of enemas. However, use of enemas before daily treatment, especially with longer RT courses, is likely to be limited due to the invasive nature of their use.25,45,46 The prescription of bowel routines in the current survey was reported by approximately 35% to 95% of respondents, varying over a broad range depending on fractionation regimen. In this study, respondents reported more frequent use of bowel instructions and preparations for delivery of SBRT relative to CFx and MHFx. This difference was most notable regarding use of enemas. Although the UK survey did not address different fractionation regimens, bowel medications were used by 63% of departments, consisting of enemas (41%), laxatives (13%), or bowel (13%).

An additional evidence-based method for reducing dose to the rectum is use of hydrogel spacers, which has been shown to improve rectal dosimetry, bowel quality of life, and reduce toxicity.25 In the current survey, use of hydrogel spacer was more common with increasing dose per fraction. Overall, recommendations and interventions were more common at higher dose per fraction (SBRT), likely reflecting concern for rectal exposure and the increasing magnitude of effect of small variances in patient set-up on dose delivered.

The adoption of image guidance techniques has improved set-up reproducibility and allowed for dose escalation and improved clinical outcomes with modern prostate directed RT.46 Daily CBCT was the most common method of image guidance reported in the current survey, with an increased use of CBCT as daily dose per fraction increased. A 2014 survey of ASTRO members regarding their use of image guided RT (IGRT) for a variety of tumor sites similarly found that CBCT or megavoltage CT was the most commonly used image guidance modality in conventionally fractionated prostate treatment at that time.21 In the current survey, the use of fiducial markers was significantly higher with increasing hypofractionation, likely demonstrating reduced tolerance of variation by the treating radiation oncologist as dose per fraction increases.

Appreciable intrafraction motion has been demonstrated during prostate RT,49 leading to the development of technologies to monitor and address this motion. The rate of electromagnetic transponder use was similar for CFx between the 2014 and current surveys (8.3% and 10.8%); however, a significant and expected increase was seen with SBRT in the current survey (18.0%). Additional studies into the long-term outcomes of patients treated with or without intrafraction monitoring would be of benefit to determine whether this improved target accuracy is of benefit and worth additional investment in cost and training and additional duration of treatment.

Image guidance is recommended for prostate RT, and literature would suggest that PTV margin expansions can be reduced with enhanced image guidance.12,44 In the 2014 ASTRO IGRT survey, median posterior PTV expansions were 5 mm (interquartile range, 3.25-5 mm) for intact prostate treated with conventional fractionation, similar to the current survey.21 The 2014 IGRT ASTRO survey demonstrated no association between the size of PTV expansions and IGRT modality, paralleling the lack of correlation seen in the current survey for those respondents using conventional fractionation. Though not addressed in the 2014 survey, associations between PTV margin expansion and image guidance were solely seen with the use of SBRT in the current data.

Similar to all survey-based research, this pattern of practice study has inherent limitations. Though the response rate in the current study mirrored those of other similar surveys,21 findings may be affected by limited response rates and associated selection bias. Further, the survey specifically targeted ASTRO members who self-identified as specializing in PCa. It is likely that other physicians who do not self-report in this fashion also deliver treatment to patients with PCa, especially in community practices. Additionally, the survey asked questions regarding the daily practices of prostate-focused radiation, and responses cannot be linked to outcome data and clinical efficacy of these patterns of practice.

Although these data suggest some implementation of the existing literature and guidelines, there are areas of inconsistency. As an example, correlations are not always apparent between the use of image guidance and PTV margin selection, similar to prior ASTRO surveys. Therefore, expanded guidelines on best practices for diet and bowel recommendations, image guidance, and associated PTVs would likely still be beneficial to help guide physicians in a standardized and evidence-based manner.

**Conclusion**

This pattern of practice survey of prostate-focused radiation oncologists describes current management
strategies employed for reproducible PCa radiation treatments, including patient instructions, choice of image guidance modality, and PTV margin expansions. Results indicate that there is heterogeneity in treatment modality, dose, patient instructions, and PTV expansions used for treatment. This survey highlights the need for further research to define best practices for patient behavioral modifications and continued guidance on evidence-based approaches for PTV margin selection, with the aim to improve overall patient outcomes and quality of life.

Acknowledgments

This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract No. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the government of the United States.

Supplementary materials

Supplementary material associated with this article can be found in the online version at doi:10.1016/j.adro.2022.100902.

References

1. Morgan SC, Hoffman K, Loblaw DA, et al. Hypofractionated radiation therapy for localized prostate cancer: Executive summary of an ASTRO, ASCO and AUA evidence-based guideline. J Urol. 2019;201:528–534.
2. Zaorsky NG, Showalter TN, Ezzell GA, et al. ACR appropriateness criteria for external beam radiation therapy treatment planning for clinically localized prostate cancer, part II of II. Adv Radiat Oncol. 2017;2:437–454.
3. Sanda MG, Cadeddu JA, Kirkby E, et al. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part II: Recommended approaches and details of specific care options. J Urol. 2018;199:990–997.
4. Zaorsky NG, Showalter TN, Ezzell GA, et al. ACR Appropriateness Criteria® external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II. Adv Radiat Oncol. 2017;2:62–84.
5. Malouf TD, Stross WC, Seneviratne DS, et al. Current use of stereotactic body radiation therapy for low and intermediate risk prostate cancer: A National Cancer Database analysis. Prostate Cancer Prostatic Dis. 2020;4:349–355.
6. Stokes WA, Kavanagh BD, Raben D, Pugh TJ. Implementation of hypofractionated prostate radiation therapy in the United States: A National Cancer Database analysis. Pract Radiat Oncol. 2017;7:270–278.
7. Hickey BE, James ML, Daly T, Soh F-Y, Jeffery M. Hypofractionation for clinically localized prostate cancer (review). Cochrane Database Syst Rev. 2019 CD011462.
8. Guo W, Sun Y, Bi J, He X, Xiao L. Hypofractionated radiotherapy versus conventional radiotherapy in patients with intermediate- to high-risk localized prostate cancer: a meta-analysis of randomized controlled trials. BMC Cancer. 2019;19:1–8.
9. Pollack A, Walker G, Horwitz EM, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol. 2013;31:3860–3868.
10. Datta NR, Stute E, Rogers S, Bodis S. Conventional versus hypofractionated radiation therapy for localized or locally advanced prostate cancer: A systematic review and meta-analysis along with therapeutic implications. Radiat Oncol Biol. 2017;99:573–589.
11. Catton CN, Lukha H, Gu C-S, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol. 2021;39:1884–1890.
12. Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHIP trial. Lancet Oncol. 2016;17:1047–1060.
13. Incrocci L, Wortel RC, Alemayehu WG, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): Final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet. 2016;17:1061–1069.
14. Kishan AU, Dang A, Katz AJ, et al. Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer. JAMA Netw Open. 2021;2:1–13.
15. Jackson WC, Silva J, Hartman HE, et al. Stereotactic body radiation therapy for localized prostate cancer: A systematic review and meta-analysis of over 6,000 patients treated on prospective studies. Int J Radiat Oncol Biol Phys. 2019;104:778–789.
16. Widmark A, Gunnlaugsson A, Beckman L, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019;394:385–395.
17. Mahase SS, Angelo DD, Kang J, Hu JC, Barbieri CE, Nagar H. Trends in the use of stereotactic body radiotherapy for treatment of prostate cancer in the United States. JAMA Netw Open. 2020;3:1–12.
18. Weiner JP, Schwartz D, Shao M, Osborn V, Choi K, Schreiber D. Stereotactic radiotherapy of the prostate: Fractionation and utilization in the United States. Radiat Oncol. 2017;35:137–143.
19. McClelland S, Sandler KA, Degnin C, Chen Y, Hung AY, Mitin T. Is moderate hypofractionation accepted as a new standard of care in North America for prostate cancer patients treated with external beam radiotherapy? Survey of genitourinary expert radiation oncologists. Int Braz J Urol. 2019;45:273–287.
20. Nightingale H, Conroy R, Elliott T, Coyle C, Wylie JP, Choudhury M, Devji N, Kehoe L, et al. To prep or not to prep - that is the question: A randomized trial on the use of antiflatulent medication as part of bowel preparation for patients having image guided external beam radiation therapy to the prostate. Pract Radiat Oncol. 2018;8:116–122.
25. Yahya S, Zarkar A, Southgate E, Nightingale P, Webster G. Which bowel preparation is best? Comparison of a high-fibre diet leaflet, daily microenema and no preparation in prostate cancer patients treated with radical radiotherapy to assess the effect on planned target volume shifts due to rectal distension. Br J Radiol. 2013;86:1031.

26. McNair HA, Wedlake L, McVey GP, Thomas K, Andreyev J, Dearnaley DP. Can diet combined with treatment scheduling achieve consistency of rectal filling in patients receiving radiotherapy to the prostate? Radiother Oncol. 2011;101:471–478.

27. Nichol AM, Warde PR, Lockwood GA, et al. A cinematic magnetic resonance imaging study of Milk of Magnesia laxative and an anti-flatulent diet to reduce intrafraction prostate motion. Int J Radiat Oncol Biol Phys. 2010;77:1072–1078.

28. Anderson NS, Yu JB, Peschel RE, Decker RH. A significant decrease in rectal volume and diameter during prostate IMRT. Radiother Oncol. 2011;98:187–191.

29. McNair HA, Wedlake L, Lips IM, Andreyev J, Van Vulpen M, Dearnaley D. A systematic review: Effectiveness of rectal emptying preparation in prostate cancer patients. Pract Radiat Oncol. 2014;4:437–447.

30. Utsumiya S, Yamamoto J, Tanabe S, et al. Complementary relationship between the improvement of dose delivery technique and PTV margin reduction in dose-escalated radiation therapy for prostate cancer. Pract Radiat Oncol. 2019;9:172–178.

31. Ariyaratne H, Chesham H, Pettingell I, Alonzi R. Image-guided radiotherapy for prostate cancer with cone beam CT: Dosimetric effects of imaging frequency and PTV margin. Radiother Oncol. 2016;121:103–108.

32. Pinkawa M, Asadpour B, Gagel B, Piroth MD, Holy R, Eble MJ. Prostate position variability and dose-volume histograms in radiotherapy for prostate cancer with full and empty bladder. Int J Radiat Oncol Biol Phys. 2006;64:856–861.

33. Nejad-Davarani SP, Sevak P, Moncion M, et al. Geometric and dosimetric impact of anatomical changes for MR-only radiation therapy for the prostate. J Appl Clin Med Phys. 2019;20:10–17.

34. Hynds S, McGarry CK, Mitchell DM, et al. Assessing the daily consistency of bladder filling using an ultrasonic bladderscan device in men receiving radical conformal radiotherapy for prostate cancer. Br J Radiol. 2001;74:813–818.

35. Pearson D, Gill SK, Campbell N, Reddy K. Dosimetric and volumetric changes in the rectum and bladder in patients receiving CBCT-guided prostate IMRT: Analysis based on daily CBCT dose calculation. J Appl Clin Med Phys. 2016;17:107–117.

36. Mullaney LM, O’Shea E, Dunne MT, et al. A randomized trial comparing bladder volume consistency during fractionated prostate radiation therapy. Pract Radiat Oncol. 2014;4:e203–e212.

37. Byun DJ, Gorovets DJ, Jacobs LM, et al. Strict bladder filling and rectal emptying during prostate SBRT: Does it make a dosimetric or clinical difference? Radiat Oncol. 2020;15:239.

38. Lardas M, Liew M, van den Bergh RC, et al. Quality of life outcomes after primary treatment for clinically localised prostate cancer: A systematic review. Eur Urol. 2017;72:869–885.

39. Sripadam R, Stratford J, Henry AM, Jackson A, Moore CJ, Price P. Rectal motion can reduce CTV coverage and increase rectal dose during prostate radiotherapy: A daily cone-beam CT study. Radiother Oncol. 2009;90:312–317.

40. Hosni A, Rosewall T, Craig T, et al. The effect of bowel preparation regime on interfraction rectal filling variation during image guided radiotherapy for prostate cancer. Radiother Oncol. 2017;12:10–15.

41. Schaefer C, Zamboglou C, Volegova-Heher N, et al. Impact of a low FODMAP diet on the amount of rectal gas and rectal volume during radiotherapy in patients with prostate cancer - A prospective pilot study. Radiat Oncol. 2020;15:27.

42. Smitsmans MHP, Pos FJ, de Bois J, et al. The influence of a dietary protocol on cone beam CT-guided radiotherapy for prostate cancer patients. Int J Radiat Oncol Biol Phys. 2008;71:1279–1286.

43. Stasi M, Munoz F, Fiorino C, et al. Emptying the rectum before treatment delivery limits the variations of rectal dose-volume parameters during 3DCRT of prostate cancer. Radiother Oncol. 2006;80:363–370.

44. Lips IM, van Gils CH, Kotte ANTI, et al. A double-blind placebo-controlled randomized clinical trial with magnesium oxide to reduce intrafraction prostate motion for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2012;83:653–660.

45. Vaver M, Foo A, Larsen T, et al. Consistency of organ geometries during prostate radiotherapy with two different bladder and bowel regimens. J Med Imaging Radiat Sci. 2015;46:380–387.

46. Choi Y, Kwak D-W, Lee H-S, et al. Effect of rectal enema on intrafraction prostate movement during image-guided radiotherapy. J Med Imaging Radiat Oncol. 2015;59:236–242.

47. Mariados N, Sylvester J, Shah D, et al. Hydrogel spacer prospective multicenter randomized controlled pivotal trial: Dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image guided intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2015;92:971–977.

48. Schulz RJ, Kagan AR. Dose escalation in the radiation therapy of prostate cancer. Int J Radiat Oncol Biol Phys. 2011;80:1289–1291.

49. Kotte ANTI, Hofman P, Lagendijk JJW, van Vulpen M, van der Heide UA. Intrafraction motion of the prostate during external-beam radiation therapy: Analysis of 427 patients with implanted fiducial markers. Int J Radiat Oncol Biol Phys. 2007;69:419–425.